Amgen Receives NMPA Approval For Repatha ® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events

Innovative LDL-C Lowering Treatment has now Been Approved for High-Risk Patients in China With Cardiovascular Disease THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the National Medical Products Administration (NMPA) has approved a new indication for Repatha® (evolocumab) as the first PCSK9 inhibitor in China for adults with established atherosclerotic cardiovascular disease (ASCVD) to reduce the risk of myocardial infarction, stroke and coronary revascularization. Low-density lipoprotein cholesterol (LDL-C) is one of the key modifiable risk factors for the development of cardiovascular disease.1,2 Decades of studies have demonstrated that...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news